Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Amneal Pharmaceuticals Inc (AMRX)
Amneal Pharmaceuticals Inc (AMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 385,595
  • Shares Outstanding, K 303,618
  • Annual Sales, $ 2,212 M
  • Annual Income, $ -129,990 K
  • 60-Month Beta 1.37
  • Price/Sales 0.18
  • Price/Cash Flow 0.91
  • Price/Book 2.13
Trade AMRX with:

Options Overview Details

View History
  • Implied Volatility 137.70% ( +137.70%)
  • Historical Volatility 59.24%
  • IV Percentile 90%
  • IV Rank 32.68%
  • IV High 411.56% on 09/30/22
  • IV Low 4.78% on 07/21/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 37
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 1,086
  • Open Int (30-Day) 1,600

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate 0.07
  • Number of Estimates 3
  • High Estimate 0.07
  • Low Estimate 0.06
  • Prior Year 0.10
  • Growth Rate Est. (year over year) -30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2400 +5.65%
on 03/28/23
2.1150 -38.06%
on 03/01/23
-0.7500 (-36.41%)
since 02/28/23
3-Month
1.2400 +5.65%
on 03/28/23
2.7400 -52.19%
on 02/09/23
-0.6600 (-33.50%)
since 12/28/22
52-Week
1.2400 +5.65%
on 03/28/23
4.6000 -71.52%
on 04/08/22
-2.8000 (-68.13%)
since 03/28/22

Most Recent Stories

More News
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates

Amneal (AMRX) delivered earnings and revenue surprises of 9.52% and 4.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AMRX : 1.3100 (+3.15%)
CSBR : 4.18 (+2.45%)
Amneal: Q4 Earnings Snapshot

Amneal: Q4 Earnings Snapshot

AMRX : 1.3100 (+3.15%)
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for naloxone hydrochloride nasal...

AMRX : 1.3100 (+3.15%)
Amneal Reports Fourth Quarter and Full Year 2022 Financial Results

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the fourth quarter and full year ended December 31, 2022.

AMRX : 1.3100 (+3.15%)
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open. The Company...

AMRX : 1.3100 (+3.15%)
Amneal Announces Strategic European Partnership with Orion Corporation

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has signed a long-term license agreement with Orion Corporation (OMXH: ORNBV & ORNAV) to commercialize a...

AMRX : 1.3100 (+3.15%)
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the Company has successfully launched 26 new generic products in 2022. In the fourth quarter of 2022,...

AMRX : 1.3100 (+3.15%)
Amneal to Participate at Upcoming Investor Conferences

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that the management team will attend the following investor conferences:

AMRX : 1.3100 (+3.15%)
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of RELEUKO ® (filgrastim-ayow), a biosimilar referencing Neupogen ® . RELEUKO ® ...

AMRX : 1.3100 (+3.15%)
FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review

Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.

CPRX : 16.72 (+2.14%)
ESPR : 1.7800 (+1.14%)
IONS : 35.48 (+3.47%)
AMRX : 1.3100 (+3.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories...

See More

Key Turning Points

3rd Resistance Point 1.3933
2nd Resistance Point 1.3567
1st Resistance Point 1.3333
Last Price 1.3100
1st Support Level 1.2733
2nd Support Level 1.2367
3rd Support Level 1.2133

See More

52-Week High 4.6000
Fibonacci 61.8% 3.3165
Fibonacci 50% 2.9200
Fibonacci 38.2% 2.5235
Last Price 1.3100
52-Week Low 1.2400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar